Selective Generation of Cytotoxic Agents at Cancer Sites
Author Information
Author(s): K.D. Bagshawel, C.J. Springer, F. Searle, P. Antoniwl, S.K. Sharma, R.G. Melton, R.F. Sherwood
Primary Institution: Cancer Research Campaign Laboratories, Department of Medical Oncology, Charing Cross Hospital
Hypothesis
Can a two-stage approach using an antibody-enzyme conjugate improve the selectivity and efficacy of cytotoxic agents at cancer sites?
Conclusion
The study demonstrates that an antibody-directed enzyme can activate a prodrug to effectively suppress tumor growth in a human cancer model.
Supporting Evidence
- The conjugate localized in the tumor and effectively converted the prodrug to an active drug.
- Significant tumor growth suppression was observed with the antibody-enzyme conjugate and prodrug treatment.
- Prodrug alone showed only slight growth delay, indicating the necessity of the conjugate for effective treatment.
Takeaway
Scientists found a way to deliver cancer-fighting drugs directly to tumors using a special enzyme that activates the drugs only where they are needed.
Methodology
The study involved conjugating a bacterial enzyme to an antibody and testing its effectiveness in mice with human cancer xenografts.
Limitations
The active drug released from the prodrug has a long half-life, which may allow it to diffuse away from the tumor site.
Participant Demographics
Nude mice bearing hCG producing CC3 xenografts of human choriocarcinoma.
Want to read the original?
Access the complete publication on the publisher's website